Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
McGill University, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
McGill University, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
McGill University, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
McGill University, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
McGill University, Medical Devices Deals, 2011 to YTD 2017 10
McGill University, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
McGill University, Pharmaceuticals & Healthcare, Deal Details 13
Partnerships 13
Lead Discovery Center Enters into Research Agreement with McGill University 13
Proove Biosciences Enters into Partnership with McGill University 14
B Cell Design Enters into R&D Agreement with McGill University 15
IASO BioMed Enters into Research Agreement with Research Institute of the McGill University 16
Cyclenium Pharma Enters into Research Agreement with McGill University 17
Neomed Institute Partners with McGill University 18
MSBi Valorisation, McGill University and Research Institute of the McGill University Health Centre Form Partnership 19
Viteava Pharma Enters Into Research Agreement With Mcgill University 20
PharmaNet Canada Forms Joint Venture With The Research Institute Of McGill University Health Centre 21
GlaxoSmithKline Enters Into Co-Development Agreement With McGill University 22
Licensing Agreements 23
Corbin Therapeutics Enters into License Agreement with McGill University 23
IASO BioMed Enters into Licensing Agreement with McGill University 24
AUM LifeTech Enters into Licensing Agreement with McGill University 25
Kinex Pharma Enters into Licensing Agreement with Hong Kong Polytechnic University and McGill University 26
PsychoGenics Enters into Licensing Agreement with McGill University for McGill-R-Thy I-APP 27
Domain Therapeutics Extends its Licensing Agreement with Universite de Montreal and McGill University 28
Viteava Pharma Enters Into Licensing Agreement For Intellectual Property Portfolio Of Analogs And Derivatives 30
Raptor Pharma Enters Into Licensing Agreement With McGill University For IP Rights Related To Malaria 32
Asset Transactions 33
Kanyr Pharma Acquires Rights for Two Cancer Programs from McGill University 33
McGill University – Key Competitors 34
McGill University – Key Employees 35
McGill University – Locations And Subsidiaries 36
Head Office 36
Other Locations & Subsidiaries 36
Joint Venture 36
Recent Developments 37
Strategy And Business Planning 37
Jan 09, 2017: Amorchem Spins Out Its USP15-deubiquitinylation (DUB) Drug Discovery Platform Into Corbin Therapeutics, With A First 1M $ Seed Investment 37
Government and Public Interest 38
Oct 23, 2017: Transformative donation of $16 million establishes new autism research centre at the Montreal Neurological Institute 38
Oct 13, 2017: New mechanism detected in Alzheimer’s disease 39
Oct 13, 2017: Neurotechnological innovation and organ-on-a-chip engineering centres receive more than $10 million in new funding 40
Sep 06, 2017: Scientists link 153 new genetic variants to osteoporosis in largest ever study 41
May 15, 2017: Diabetes drug may help symptoms of autism associated condition 42
Jan 09, 2017: Breakthrough in MS treatment 43
Oct 18, 2016: RI-MUHC researchers discover new path to stop the spread of cancer 44
Oct 03, 2016: KalGene gears up to manufacture and test promising Alzheimer’s treatment with NRC, McGill and CIMTEC 45
Sep 22, 2016: Kenneth Rainin Foundation Awards Over $3 Million to High-Risk, High Reward Inflammatory Bowel Disease Research Projects 46
Sep 15, 2016: €12.6 Million Awarded to 3 Projects in Global Effort to End Progressive Multiple Sclerosis 48
Sep 07, 2016: Medication against schizophrenia inhibits pancreatic cancer 50
Sep 06, 2016: McGill wins $84 million grant for neuroscience 51
Sep 01, 2016: Ferring Canada Donates $2 Million to McGill University 52
Aug 15, 2016: Legions of nanorobots target cancerous tumours with precision – Administering anti-cancer drugs redefined 53
Aug 01, 2016: Adverse Effects and Incretin-based Drugs for Diabetes 54
Apr 20, 2016: Brighter prospects for chronic pain 55
Feb 15, 2016: Vulnerability to depression linked to noradrenaline 56
Jan 20, 2016: Using light for targeted drug delivery could help fight tumors, local infections 57
Other Significant Developments 58
Oct 20, 2016: Easing the burden of terminal illness 58
Appendix 59
Methodology 59
About GlobalData 59
Contact Us 59
Disclaimer 59
McGill University, Pharmaceuticals & Healthcare, Key Facts 2
McGill University, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
McGill University, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
McGill University, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
McGill University, Deals By Therapy Area, 2011 to YTD 2017 9
McGill University, Medical Devices Deals, 2011 to YTD 2017 10
McGill University, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Lead Discovery Center Enters into Research Agreement with McGill University 13
Proove Biosciences Enters into Partnership with McGill University 14
B Cell Design Enters into R&D Agreement with McGill University 15
IASO BioMed Enters into Research Agreement with Research Institute of the McGill University 16
Cyclenium Pharma Enters into Research Agreement with McGill University 17
Neomed Institute Partners with McGill University 18
MSBi Valorisation, McGill University and Research Institute of the McGill University Health Centre Form Partnership 19
Viteava Pharma Enters Into Research Agreement With Mcgill University 20
PharmaNet Canada Forms Joint Venture With The Research Institute Of McGill University Health Centre 21
GlaxoSmithKline Enters Into Co-Development Agreement With McGill University 22
Corbin Therapeutics Enters into License Agreement with McGill University 23
IASO BioMed Enters into Licensing Agreement with McGill University 24
AUM LifeTech Enters into Licensing Agreement with McGill University 25
Kinex Pharma Enters into Licensing Agreement with Hong Kong Polytechnic University and McGill University 26
PsychoGenics Enters into Licensing Agreement with McGill University for McGill-R-Thy I-APP 27
Domain Therapeutics Extends its Licensing Agreement with Universite de Montreal and McGill University 28
Viteava Pharma Enters Into Licensing Agreement For Intellectual Property Portfolio Of Analogs And Derivatives 30
Raptor Pharma Enters Into Licensing Agreement With McGill University For IP Rights Related To Malaria 32
Kanyr Pharma Acquires Rights for Two Cancer Programs from McGill University 33
McGill University, Key Competitors 34
McGill University, Key Employees 35
McGill University, Subsidiaries 36
McGill University, Joint Venture 36